Topics

MorphoSys AG: MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

17:56 EDT 19 Mar 2019 | FinanzNachrichten

PLANEGG/MUNICH GERMANY and SHANGHAI, China / ACCESSWIRE / March 19, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based cli...

Original Article: MorphoSys AG: MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

NEXT ARTICLE

More From BioPortfolio on "MorphoSys AG: MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma"

Quick Search